3AA Limited Human
Thyrotropin TRH
FDA-approved diagnostic tripeptide that drives the hypothalamic-pituitary-thyroid axis and acts as a broad CNS neuromodulator — with 14,823 PubMed publications spanning neuroprotection, spinocerebellar ataxia, spinal cord injury, depression, and arousal.
In Plain English:
TRH (thyrotropin-releasing hormone), also called protirelin, is a tiny three-amino-acid peptide your hypothalamus makes to tell your pituitary to release thyroid-stimulating hormone (TSH). It was the first hypothalamic releasing factor ever chemically identified (Nobel work, 1969), and it earned FDA approval as Thyrel TRH for diagnostic thyroid testing. Beyond the thyroid axis, TRH is distributed throughout the brain and spinal cord, acting as a general 'wake up and recover' signal: it counteracts opioid-induced sedation, boosts arousal and locomotion, reduces anxiety in stressed animals, protects neurons from ischemia and trauma, and improves motor function in patients with spinocerebellar degeneration. Its main practical limitation is a plasma half-life of roughly five minutes — it's enzymatically shredded in blood within minutes — which is why researchers are actively developing intranasal nanoparticle delivery, stable TRH analogs (taltirelin, rovatirelin), and continuous IV infusion protocols to extend its effects. In Japan, rovatirelin (a long-acting oral analog) has been approved for spinocerebellar degeneration, and IV protirelin has shown statistically significant improvements in ataxia scores in clinical trials.
Research Maturity
Limited Human (~14,800 PubMed publications; FDA-approved diagnostic (Thyrel TRH); human trials in several CNS conditions+ Studies)
Focus
Endocrine Diagnostics
Thyroid Axis Modulation
Origin
Isolated and sequenced simultaneously in 1969 by Roger Guillemin (Salk Institute) and Andrew Schally (Tulane University), an achievement that earned them the 1977 Nobel Prize in Physiology or Medicine. TRH was the first hypothalamic releasing hormone to be structurally characterized; Guillemin's team required 500,000 sheep hypothalami to isolate 1 mg of the peptide. The tripeptide sequence — pyroglutamyl-histidyl-proline amide (pGlu-His-Pro-NH2) — was confirmed synthetically and found to be identical across virtually all vertebrate species examined. TRH-like immunoreactivity is present not only in the hypothalamic paraventricular nucleus but throughout the limbic system, brainstem, spinal cord, retina, pancreas, and gut, indicating roles far beyond its classical endocrine function.
Mechanism
Three interlocking mechanisms: (1) Endocrine axis — TRH neurons in the hypothalamic paraventricular nucleus (PVN) project to the median eminence and release TRH into the portal capillaries; TRH binds TRHR1 on anterior pituitary thyrotrophs, activating Gq/phospholipase C, IP3-mediated calcium release, and PKC, triggering TSH and prolactin secretion. Thyroid hormones (T3/T4) close the loop via negative feedback on both TRH transcription and pituitary TRHR expression. (2) Neuromodulatory — extrahypothalamic TRH acts as a CNS neuromodulator: it antagonises barbiturate- and ethanol-induced sedation, opposes the hypothermic/analgesic actions of opioids, and potentiates cholinergic transmission in the hippocampus. It inhibits NPY and somatostatin, stimulates catecholamine turnover, and interacts with MAPK and PI3K cascades in neurons. (3) Neuroprotective — TRH reduces excitotoxic glutamate toxicity, decreases hippocampal apoptosis following ischemia (taltirelin, 1 mg/mL ICV reduced caspase-3 activation), inhibits tau phosphorylation in Alzheimer models, and increases spinal cord blood flow while antagonising leukotrienes and reactive oxygen species after traumatic injury. Biosynthesis from preproTRH (255 aa precursor) involves PC1/3 and PC2 convertases acting during regulated secretory pathway transit; the mature tripeptide is flanked by Lys-Arg processing sites within six tandemly repeated TRH copies in the precursor.
Outcome
TSH release (peak +20–30 min post-IV, baseline by ~3 h); prolactin release (rapid, parallel to TSH); growth hormone elevation in ~65% of acromegalic patients; spinocerebellar ataxia scores (SARA: statistically significant improvement p=0.005 with IV protirelin 2 mg/day x14 days; rovatirelin oral 1.6–2.4 mg/day x~2 years reduced truncal and limb ataxia in phase 3 trial); motor execution (reduced baseline reaching error p=0.021 in prism adaptation task, SCD patients); spinal cord injury motor and sensory function (improved with 0.2 mg/kg IV bolus + 0.2 mg/kg/h x6 h); opioid-induced respiratory depression reversal (dose-dependent in animals; human IV results inconsistent); neuroprotection post-ischemia (delayed treatment up to 24 h still effective in rodent models); Alzheimer cognitive dysfunction (ameliorated at 0.1 mg/kg IV in rodent models); fatigue (IV TRH 0.5–1.5 mg/week x4 weeks improved self-reported energy in human trial); upper motor neuron spasticity (statistically significant improvement in placebo-controlled trial); ALS motor neuron function (transient improvement ~1 h post-infusion); epilepsy (West syndrome, Lennox-Gastaut, complex partial seizures — human case series positive, no RCT); appetite suppression (nucleus accumbens TRH injection reduced palatable food intake in rats via α-MSH pathway).
